MSCM
JAZZ icon

McElhenny Sheffield Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

McElhenny Sheffield Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11
Closed -$1.75K – 354
2022
Q4 		$1.75K Buy
+11
New +$1.61K ﹤0.01% 509

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

McElhenny Sheffield Capital Management's JAZZ Position: Q1 2023 in Review

McElhenny Sheffield Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 11 shares — an estimated $1.75K sold.

McElhenny Sheffield Capital Management first reported a position in JAZZ in Q4 2022 and held it in 1 quarter. The position peaked at $1.75K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

  • McElhenny Sheffield Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • McElhenny Sheffield Capital Management sold 11 Jazz Pharmaceuticals shares in Q1 2023, an estimated $1.75K.
  • McElhenny Sheffield Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • McElhenny Sheffield Capital Management's Jazz Pharmaceuticals position peaked at $1.75K in Q4 2022.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on McElhenny Sheffield Capital Management's 13F filing for Q1 2023, filed 13 Apr 2023.